MedTrace Logo

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects

NCT05907382 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2023-06-18

No results posted yet for this study

Summary

Safety, tolerability, pharmacokinetics, and pharmacodynamics of JMKX003002 in single and multiple ascending dose randomized，doubled-blind phase 1 study in healthy subjects

Conditions

  • Safety and Tolerability

Interventions

DRUG

JMKX003002 will be administered orally

oral once

DRUG

JMKX003002 will be administered orally

oral once

DRUG

JMKX003002 will be administered orally

oral once

DRUG

Placebo in Cohorts 1 to 5

oral once

DRUG

Placebo in 2 Cohorts

oral once

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Jing Zhang · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-09
Primary Completion
2023-12-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05907382 on ClinicalTrials.gov